Access to anti-retroviral drugs, female in Belgium

Belgium: Access to anti-retroviral drugs, female was 89.0% in 2023. ▲ Rising

Latest (2023)
89.0%
Change on year
unchanged
World rank
35th
of 141 countries
All-time high
90.0%
in 2017
All-time low
41.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, female in Belgium, 2000–2023

0204060801002000201120232000: 41 %2001: 46 %2002: 51 %2003: 55 %2004: 60 %2005: 64 %2006: 77 %2007: 77 %2008: 80 %2009: 82 %2010: 85 %2011: 88 %2012: 84 %2013: 86 %2014: 86 %2015: 87 %2016: 88 %2017: 90 %2018: 89 %2019: 87 %2020: 87 %2021: 87 %2022: 89 %2023: 89 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, female in Belgium is 89.0%, measured in 2023.

The figure is up 3.5% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Belgium peaked at 90.0% in 2017 and was at its lowest, 41.0%, in 2000.

Belgium ranks 35th of 141 countries on this measure, in the top quarter.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, female in Belgium, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Belgium, 2000 to 2023.
Year % Change
2000 41.0%
2001 46.0% +12.2%
2002 51.0% +10.9%
2003 55.0% +7.8%
2004 60.0% +9.1%
2005 64.0% +6.7%
2006 77.0% +20.3%
2007 77.0% +0.0%
2008 80.0% +3.9%
2009 82.0% +2.5%
2010 85.0% +3.7%
2011 88.0% +3.5%
2012 84.0% -4.5%
2013 86.0% +2.4%
2014 86.0% +0.0%
2015 87.0% +1.2%
2016 88.0% +1.1%
2017 90.0% +2.3%
2018 89.0% -1.1%
2019 87.0% -2.2%
2020 87.0% +0.0%
2021 87.0% +0.0%
2022 89.0% +2.3%
2023 89.0% +0.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 63.3% 41.0% 82.0% 10
2010s 87.0% 84.0% 90.0% 10
2020s 88.0% 87.0% 89.0% 4

Countries ranked near Belgium

  1. 35 Argentina 89.0% compare
  2. 35 Cambodia 89.0% compare
  3. 35 Croatia 89.0% compare
  4. 35 Guinea-Bissau 89.0% compare
  5. 35 Italy 89.0% compare
  6. 35 Netherlands 89.0% compare
  7. 35 Nigeria 89.0% compare
  8. 35 Spain 89.0% compare

See the full ranking of 160 places →

More gender data for Belgium

All data for Belgium →

Frequently asked questions

What is access to anti-retroviral drugs, female in Belgium?
Access to anti-retroviral drugs, female in Belgium was 89.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Belgium?
The highest recorded value was 90.0% in 2017.
What is the lowest access to anti-retroviral drugs, female recorded in Belgium?
The lowest recorded value was 41.0% in 2000.
How does Belgium rank for access to anti-retroviral drugs, female?
Belgium ranks 35th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, female rising or falling in Belgium?
Over the last ten years it is up 3.5%. The long-run trend across the full record is rising.
Where does this Belgium data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Belgium. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/belgium/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/belgium/">Access to anti-retroviral drugs, female in Belgium</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.